The Therapeutic Effect of Monotherapy and Combined Therapy for Androgen Blockade in Patients with Metastatic Prostate Cancer / 대한비뇨기과학회지
Korean Journal of Urology
;
: 12-16, 2003.
Artigo
em Coreano
| WPRIM
| ID: wpr-130906
ABSTRACT
PURPOSE:
We evaluated the therapeutic effect of combined androgen blockade (CAB) compared with that of medical, or surgical, castration monotherapy, in the treatment of the metastatic prostate cancer. MATERIALS ANDMETHODS:
Of 53 patients with metastatic prostate cancer, we compared the overall survival between CAB and monotherapy groups, using a Kaplan-Meier survival curve. We also compared the therapeutic effect of flutamide and bicalutamide in the CAB group.RESULTS:
There were no differences in known prognostic factors between the CAB and monotherapy groups. The mean survival after treatment were 43 months in the CAB group, and 38 months in monotherapy group, with no significant difference (p=0.470). There were also no differences in the survival rates between the flutamide and bicalutamide groups (p=0.158).CONCLUSIONS:
These results implicate that the CAB was no better than medical, or surgical, castration monotherapy in patients with metastatic prostate cancer, and that flutamide or bicalutamide, in CAB, resulted in similar efficacies and tolerabilities.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Próstata
/
Neoplasias da Próstata
/
Castração
/
Taxa de Sobrevida
/
Flutamida
/
Metástase Neoplásica
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Urology
Ano de publicação:
2003
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS